Thymoquinone ameliorates symptoms of Parkinson's disease in a 6-OHDA rat model by downregulation of miR-204-3p

Basit Öğe Kaydı
dc.contributor.authorPala, Mukaddes
dc.contributor.authorMeral, Ismail
dc.contributor.authorAcikgoz, Nilguen Pala
dc.contributor.authorMengi, Murat
dc.contributor.authorGokce, Meryem Betul Erdim
dc.contributor.authorUnsal, Rumeysa
dc.contributor.authorPolat, Yalcin
dc.date.accessioned2024-10-29T17:58:39Z
dc.date.available2024-10-29T17:58:39Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractmicroRNAs (miRNAs) play a significant role in the pathophysiology of Parkinson's disease. In this study, we evaluated the neuroprotective effect of thymoquinone on the expression profiles of miRNA and cognitive functions in the 6-hydroxydopamine (6-OHDA)-induced Parkinson's model. Male adult Wistar albino rats (200-230 g, n = 36) were randomly assigned to six groups: Sham, thymoquinone (10 mg/kg, p.o.), 6-OHDA, 6-OHDA + thymoquinone (10 mg/kg), 6-OHDA + thymoquinone (20 mg/kg), and 6-OHDA + thymoquinone (50 mg/kg). Behavioral changes were detected using the open field and the elevated plus maze tests. The mature 728 miRNA expressions were evaluated by miRNA microarray (GeneChip miRNA 4.0). Ten miRNAs were selected (rno-miR-212-5p, rno-miR-146b-5p, rno-miR-150-5p, rno-miR-29b-2-5p, rno-miR-126a-3p, rno-miR-187-3p, rno-miR-34a-5p, rno-miR-181d-5p, rno-miR-204-3p, and rno-miR-30c-2-3p) and confirmed by real-time PCR. Striatum samples were stained with hematoxylin-eosin to determine the effect of dopaminergic lesions. One-way ANOVA test and independent sample t-test were used for statistical analyses. rno-miR-204-3p was upregulated at 6-OHDA and downregulated at the 50 mg/kg dose of thymoquinone. In conclusion, thymoquinone at a dose of 50 mg/kg ameliorates symptoms of Parkinson's disease in a 6-OHDA rat model by downregulation of miR-204-3p. Also, the results showed that thymoquinone can improve locomotor activity and willing exploration and decreased anxiety. Therefore, thymoquinone can be used as a therapeutic agent.
dc.description.sponsorshipBezmialem Vakimath;f University [12.2014/17]
dc.description.sponsorshipThe present work was funded by the Research Fund of Bezmialem Vak & imath;f University (grant number 12.2014/17).
dc.identifier.doi10.1097/FBP.0000000000000776
dc.identifier.endpage210
dc.identifier.issn0955-8810
dc.identifier.issn1473-5849
dc.identifier.issue4en_US
dc.identifier.pmid38660812
dc.identifier.scopus2-s2.0-85192402770
dc.identifier.scopusqualityQ3
dc.identifier.startpage201
dc.identifier.urihttps://doi.org/10.1097/FBP.0000000000000776
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14437
dc.identifier.volume35
dc.identifier.wosWOS:001275445600003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofBehavioural Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject6-OHDA
dc.subjectbehavioral tests
dc.subjectmiR-204-3p
dc.subjectParkinson disease
dc.subjectthymoquinone
dc.titleThymoquinone ameliorates symptoms of Parkinson's disease in a 6-OHDA rat model by downregulation of miR-204-3p
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu